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Oral emergency contraception (EC) is available as levonorgestrel and ulipristal acetate. In England, 
EC is available through a variety of settings and can be obtained without a prescription. In 2014, 
evidence from clinical studies prompted a review of available evidence by the European Medicine 
Agency’s Committee for Medicinal Products for Human Use to assess whether increased bodyweight 
reduces the efficacy of EC. The review concluded that available data were inconclusive.1,2 However, 
if future research were to substantiate a relationship of reduced EC efficacy in women with higher 
bodyweight, it would be important to understand the potential impact at a population level. We 
used data from the Health Survey for England (HSE) 20103 to explore this. 
 
HSE is an annually-conducted, nationally-representative probabilistic household survey of the 
general population resident in England.  Details of HSE methodology are reported elsewhere.4,5 
Demographic data are collected using face to face interviews and self-completed questionnaire 
booklets. Bodyweight is measured at a nurse visit. In 2010, the survey incorporated questions 
regarding sexual behaviour and contraceptive use, including EC use in the 12 months preceding the 
interview.  We estimated EC use in 1,508 sexually-experienced (reporting at least one sexual partner 
over the lifetime to the date of the interview) 16 to 44 year-old women by bodyweight. Data were 
analysed in Stata 12.1 accounting for weighting, clustering and stratification of the data.   
EC use in the last year was reported by 9% (95% CI 7%-11%) of all sexually-experienced 16-44 year-
old women and was more frequently reported among younger women (Table 1). Among those who 
reported EC use in the last year, 33% (95% CI 25%-43%) had a bodyweight >75kg and 22% (95% CI 




Table 1: Percentage of women who reported oral emergency contraception use in the last year 
(sexually-experienced women aged 16-44 years) 
 
Used EC in last year 
(95% confidence interval) 
Overall 9% (7%-11%) 
By age group (years)  
16-24 20% (16%-26%) 
25-34 8% (6%-11%) 
35-44 3% (2%-5%) 
 
Current guidance advises EC use regardless of bodyweight,1 although available data remain 
inconclusive with regard to the relationship with EC efficacy.1,2  Our analysis demonstrates that EC 
could be less effective in a substantial proportion of current EC users if efficacy were found to be 
lower among those with higher bodyweight. If future provision of EC is reliant on some measure of 
bodyweight, this would have serious implications in the delivery of EC, especially in settings where 
the threshold for access to EC is low, such as pharmacies. Younger women would be particularly 
affected given the higher rates of EC use in this group. Research is urgently needed to determine the 
relationship between bodyweight and EC efficacy. 
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